Thyrocare Q4 Results Review - Efforts To Improvise Volume Growth Are Materialising: ICICI Securities

ICICI Securities Report

Thyrocare Technologies Ltd.’s core business grew 18% YoY in Q4 FY24 driven by 13% YoY jump in sales from franchisee and 40% from partnerships (excluding API and B2G).

Ebitda margin at 21.9% was weaker (our estimate: 25.1%) as the company has inched up investments in marketing and promotion for new bundled test programmes like Jaanch, Her Check and Troponin I and for other initiatives.

Newly launched bundled test packages like Jaanch and Her Check have been well received by the market and are clocking monthly sales of Rs 10 million each.

Besides, Thyrocare has started operations in Tanzania in April 2024. Management expects mid-teen revenue growth with flattish Ebitda (ex-ESOP and provisions) margin in FY25.

We raise FY25/26E revenue by 3% each though cut earnings by 1-2%. Maintain Buy with higher target price of Rs 750.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.